# DEC - 9 2009

# 510(k) SUMMARY

This summary of $5 1 0 ( \mathbf { k } )$ safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

The assigned 510(k) number is K091884.

807.92 (a)(1): Name:

ARK Diagnostics, Inc.

Address:

1190 Bordeaux Drive Sunnyvale, CA 94089

Owner Operator Number: 10027663   
Establishment Registration: 3005755244

Phone: (408) 747-0700   
FAX: (408) 747-0783   
Contact: Kenneth C. Kasper, PhD - (408) 747-0708 Executive Director of Quality and Regulatory Affairs

Date prepared: November 24, 2009

807.92 (a)(2): Device name- trade name and common name, and classification

Trade name:

ARKTM Zonisamide Assay ARKTM Zonisamide Calibrator ARK TM Zonisamide Control

Common Name: Homogeneous Enzyme Immunoassay

Classification: 21 CFR 862.3350 NWM Diphenylhydantoin Test System; Class II (21 CFR 862.3200 DLJ, 21 CFR 862.3280 LAS)

# 807.92 (a)(3): Identification of the legally marketed predicate device

K051211 QMS® Zonisamide Assay, QMS $\otimes$ Zonisamide Calibrator Set, QMS $\mathfrak { B }$ Zonisamide Control Set

# 807.92 (a)(4): Device Description

The ARK Zonisamide Assay is a homogeneous immunoassay based on competition between drug in the specimen and zonisamide labeled with the enzyme glucose-6-phosphate dehydrogenase (G6PDH) for binding to the antibody reagent. As the latter binds antibody, enzyme activity decreases. In the presence of drug from the specimen, enzyme activity increases and is directly proportional to the drug concentration. Active enzyme converts the coenzyme nicotinamide adenine dinucleotide (NAD) to NADH that is measured spectrophotometrically as a rate of change in absorbance. Endogenous serum G6PDH does not interfere with the results because the coenyzme NAD functions only with the bacterial enzyme used in the assay.

The ARK Zonisamide Assay consists of reagents R1 anti-zonisamide polyclonal antibody with substrate and R2 zonisamide labeled with bacterial G6PDH enzyme. The ARK Zonisamide Calibrator consists of a six-level set to calibrate the assay, and the ARK Zonisamide Control consists of a three-level set used for quality control of the assay.

# 807.92 (a)(5): Intended Use / Indications for Use

The ARKTM Zonisamide Assay is a homogeneous enzyme immunoassay intended for the quantitative determination of zonisamide in human serum or plasma samples on automated clinical chemistry analyzers. Zonisamide concentrations can be used as an aid in management of patients treated with zonisamide.

The ARKTM Zonisamide Calibrator is intended for use in calibration of the ARK Zonisamide Assay.

The ARKTM Zonisamide Control is intended for use in quality control of the ARK Zonisamide Assay.

# 807.92 (a)(6): Technological Similarities and Differences to the Predicate

# SUBSTANTIAL EQUIVALENCE COMPARATIVE CHART

Comparison between the ARK™ Zonisamide Assay and the Seradyn QMS@ Zonisamide Assay   

<table><tr><td rowspan=1 colspan=1>Characteristic</td><td rowspan=1 colspan=1>DeviceARKTM Zonisamide Assay</td><td rowspan=1 colspan=1>PredicateQMS® Zonisamide Assay K051211</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>The ARKTM Zonisamide Assay is intendedfor the quantitative determination ofzonisamide in human serum or plasma onautomated clinical chemistry analyzers.</td><td rowspan=1 colspan=1>The QMS® Zonisamide Assay is intendedfor the quantitative determination ofzonisamide in human serum or plasmasamples.</td></tr><tr><td rowspan=1 colspan=1>Indications for Use</td><td rowspan=1 colspan=1>Zonisamide concentrations can be used as anaid in management of patients treated withzonisamide.</td><td rowspan=1 colspan=1>Zonisamide concentrations can be used as anaid in management of patients treated withzonisamide.</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Serum or plasma</td><td rowspan=1 colspan=1>Serum or plasma</td></tr><tr><td rowspan=1 colspan=1>Methodology</td><td rowspan=1 colspan=1>Homogenous enzyme immunoassay (EIA)</td><td rowspan=1 colspan=1>Homogenous particle-enhanced turbidimetricimmunoassay</td></tr><tr><td rowspan=1 colspan=1>ReagentComponents</td><td rowspan=1 colspan=1>Two (2) reagent system:Anti-zonisamide Antibody/Substrate Reagent(R1) containing rabbit polyclonal antibodiesto zonisamide, glucose-6-phosphate,nicotinamide adenine dinucleotide, bovineserum albumin, preservatives, and stabilizersEnzyme Reagent (R2) containing zonisamidelabeled with bacterial G6PDH, buffer, bovineserum albumin, preservatives, and stabilizersNo special handling required. Reagents donot contain azide.</td><td rowspan=1 colspan=1>Two (2) reagent system:The device consists of ready-to-use reagentscontaining rabbit polyclonal zonisamideantibodies in buffer (R1), and zonisamide-coated microparticles with (R2), both withazide preservative.</td></tr><tr><td rowspan=1 colspan=1>Platform required</td><td rowspan=1 colspan=1>Automated clinical chemistry analyzerValidated on Hitachi 917</td><td rowspan=1 colspan=1>Automated clinical chemistry analyzerValidated on Hitachi 717</td></tr><tr><td rowspan=1 colspan=1>Accessory reagents</td><td rowspan=1 colspan=1>Calibrators (six levels) and controls (threelevels</td><td rowspan=1 colspan=1>Calibrators (six levels) and controls (threelevels)</td></tr><tr><td rowspan=1 colspan=1>Testingenvironment</td><td rowspan=1 colspan=1>Routine clinical laboratory</td><td rowspan=1 colspan=1>Routine clinical laboratory</td></tr><tr><td rowspan=1 colspan=1>Reagent conditionand storage</td><td rowspan=1 colspan=1>Liquid, 2-8° C</td><td rowspan=1 colspan=1>Liquid, 2-8° C</td></tr></table>

# 807.92 (b)(1) and 807.92 (b)(2): Brief Description of Nonclinical and Clinical Data

Limit of Quantitation (LOQ)

The LOQ of the ARK Zonisamide Assay was determined according to CLSI EP17-A and is defined as the lowest concentration for which acceptable inter-assay precision and recovery is observed $( \leq 2 0 \%$ CV with $\pm 1 5 \%$ recovery). The LOQ was determined to be $2 . 0 ~ \mu \mathrm { g / m L }$ .

# Recovery

Analytical recovery was performed by adding concentrated zonisamide drug into human serum negative for zonisamide. A stock concentrate of highly pure zonisamide was added volumetrically to human serum negative for zonisamide, representing drug concentrations across the assay range. Twenty replicates of each sample were assayed. The results were averaged and compared to the target concentration and percent recovery calculated. Results are shown below.

% Recovery $\mathit { \Theta } = 1 0 0$ X Mean recovered concentration Theoretical concentration   

<table><tr><td>Theoretical Concentration (μg/mL)</td><td>Mean Recovered Concentration (μg/mL)</td><td>Percent Recovery</td></tr><tr><td>2.0</td><td>1.7</td><td>85.3</td></tr><tr><td>3.0</td><td>3.0</td><td>100.0</td></tr><tr><td>5.0</td><td>5.5</td><td>110.0</td></tr><tr><td>15.0</td><td>15.7</td><td>104.5</td></tr><tr><td>25.0</td><td>25.3</td><td>101.0</td></tr><tr><td>35.0</td><td>35.0</td><td>100.0</td></tr><tr><td>50.0</td><td>49.1</td><td>98.1</td></tr></table>

# Linearity

Linearity studies were performed as suggested in CLSI/NCCLS Protocol EP6-A. An $8 0 . 0 ~ \mu \mathrm { g / m L }$ EY serum sample was prepared and dilutions were made proportionally with human serum negative for zonisamide. Zonisamide concentrations ranged from 0.8 to ${ 8 0 . 0 \ \mu \mathrm { g / m L } }$ . Linearity at specific dilutions was considered acceptable if the percent difference was $\pm 1 0 \%$ between the predicted $1 ^ { \mathfrak { s t } }$ and $2 ^ { \mathsf { n d } }$ order regressed values or $\pm 1 5 \%$ below $3 . 0 ~ \mu \mathrm { g / m L }$ .A linear relationship between 2.4 and $4 8 . 0 ~ \mu \mathrm { g / m L }$ is shown below.

<table><tr><td>Estimated Value</td><td>Results (μg/mL)</td><td>1st Order Predicted Results</td><td>2nd Order Predicted Results</td><td>% Difference</td></tr><tr><td>(μg/mL) 2.4</td><td>2.3</td><td>2.5</td><td>2.3</td><td>-7.0</td></tr><tr><td>3.2</td><td>3.2</td><td>3.3</td><td>3.2</td><td>-3.8</td></tr><tr><td>4.0</td><td>4.1</td><td>4.1</td><td>4.0</td><td>-1.8</td></tr><tr><td>4.8</td><td>4.8</td><td>4.8</td><td>4.8</td><td>-0.6</td></tr><tr><td>5.6</td><td>5.8</td><td>5.6</td><td>5.6</td><td>0.3</td></tr><tr><td>6.4</td><td>6.7</td><td>6.4</td><td>6.5</td><td>1.0</td></tr><tr><td>7.2</td><td>7.4</td><td>7.2</td><td>7.3</td><td>1.4</td></tr><tr><td>8.0</td><td>8.2</td><td>8.0</td><td>8.1</td><td>1.8</td></tr><tr><td>16.0</td><td>16.2</td><td>15.7</td><td>16.2</td><td>2.7</td></tr><tr><td>24.0</td><td>23.4</td><td>23.5</td><td>24.0</td><td>2.3</td></tr><tr><td>32.0</td><td>32.0</td><td>31.3</td><td>31.7</td><td>1.4</td></tr><tr><td>40.0</td><td>39.7</td><td>39.1</td><td>39.2</td><td>0.4</td></tr><tr><td>48.0</td><td>45.8</td><td>46.8</td><td>46.5</td><td>-0.7</td></tr></table>

# Assay Range

The range of the assay is 2.0 to $5 0 . 0 ~ { \mu \mathrm { g / m L } }$ . Report results below this range as $< 2 . 0 ~ \mu \mathrm { g / m L }$ - Report results above this range $\mathfrak { u s } > 5 0 . 0 \ \mu \mathrm { g / m L }$ .

Specimens testing initially above the assay range may be diluted in Calibrator A and retested. Multiply the assay result by the dilution factor to obtain the concentration of zonisamide in the undiluted specimen. The concentration after dilution must exceed the limit of quantitation and fall within the measuring range.

Correlation studies were performed using CLSI/NCCLS Protocol EP9-A2. Results from the ARK Zonisamide Assay were compared with results from a turbidimetric immunoassay. The zonisamide concentrations ranged from $6 ~ \mu \mu / \mu \nu$ to $4 5 ~ \mu \mathrm { g / m L }$ . Results of the Passing-Bablok regression analysis for the study are shown below with $9 5 \%$ confidence limits shown in parentheses.

<table><tr><td>Slope</td><td>1.00</td><td>(0.96 to 1.00)</td></tr><tr><td>y-intercept</td><td>- 1.00</td><td>(- 1.00 to - 0.46)</td></tr><tr><td>Correlation Coefficient (r²)</td><td>0.93</td><td>(0.91 to 0.95)</td></tr><tr><td>Number of Samples</td><td>176</td><td></td></tr></table>

# Precision

Precision was determined as described in CLSI/NCCLS Protocol EP5-A2. Tri-level controls containing zonisamide and pooled human serum specimens were used in the study. Each level of control was assayed in quadruplicate twice a day for 20 days. Each of the runs per day was separated by at least two hours. The within run, between day, total SD, and percent CVs were calculated. Results are shown below. Acceptance criteria: ${ < } 1 0 \%$ total CV.

<table><tr><td rowspan="2">Sample</td><td rowspan="2">N</td><td rowspan="2">Mean (μg/mL)</td><td colspan="2">Within Run</td><td colspan="2">Between Day</td><td colspan="2">Total</td></tr><tr><td>SD</td><td>CV (%)</td><td>SD</td><td>CV (%)</td><td>SD</td><td>CV (%)</td></tr><tr><td colspan="9">ARK Zonisamide Control</td></tr><tr><td>LOW</td><td>160</td><td>5.0</td><td>0.21</td><td>4.1</td><td>0.16</td><td>3.2</td><td>0.25</td><td>5.1</td></tr><tr><td>MID</td><td>160</td><td>24.4</td><td>0.96</td><td>3.8</td><td>0.56</td><td>2.3</td><td>1.12</td><td>4.5</td></tr><tr><td>HIGH</td><td>160</td><td>50.6</td><td>1.97</td><td>3.9</td><td>1.33</td><td>2.6</td><td>2.63</td><td>5.3</td></tr><tr><td colspan="9">Human Serum</td></tr><tr><td>LOW</td><td>160</td><td>7.0</td><td>0.29</td><td>4.0</td><td>0.21</td><td>3.0</td><td>0.36</td><td>4.9</td></tr><tr><td>MID</td><td>160</td><td>22.6</td><td>0.81</td><td>3.5</td><td>0.59</td><td>2.6</td><td>1.01</td><td>4.4</td></tr><tr><td>HIGH</td><td>160</td><td>51.6 ,</td><td>2.47</td><td>4.9</td><td>1.66</td><td>3.2</td><td>2.96</td><td>5.9</td></tr></table>

Interference studies were conducted using CLSI/NCCLS Protocol EP7-A2 as a guideline. Clinically high concentrations of the following potentially interfering substances in serum with known levels of zonisamide (approximately 15 and $4 5 ~ { \mu \mathrm { g / m L } }$ were evaluated. Each sample was assayed using the ARK Zonisamide Assay, along with a serum control of zonisamide. Measurement of zonisamide resulted in $\leq 1 0 \%$ error in the presence of interfering substances at the levels tested.

<table><tr><td colspan="3"></td><td colspan="2">Percentage Recovery</td></tr><tr><td>Interfering Substance</td><td></td><td>Interferent Concentration</td><td>15 μg/mL Zonisamide</td><td>45 μg/mL Zonisamide</td></tr><tr><td>Albumin</td><td></td><td>12 g/dL</td><td>103.3</td><td>97.9</td></tr><tr><td>Bilirubin - conjugated</td><td></td><td>70 mg/dL -</td><td>102.8</td><td>101.0</td></tr><tr><td>Bilirubin - unconjugated</td><td></td><td>70 mg/dL</td><td>100.1</td><td>98.8</td></tr><tr><td>Cholesterol</td><td></td><td>651 mg/dL</td><td>98.5</td><td>97.0</td></tr><tr><td>Gamma-Globulin</td><td></td><td>12 g/dL</td><td>97.3</td><td>101.4</td></tr><tr><td></td><td></td><td>1000 mg/dL</td><td>96.6</td><td></td></tr><tr><td>Hemoglobin Intralipid</td><td></td><td>1500 mg/dL</td><td></td><td>104.1</td></tr><tr><td></td><td></td><td>1 100 IU/mL</td><td>94.8</td><td>94.7</td></tr><tr><td>Rheumatoid Factor</td><td></td><td></td><td>98.4</td><td>100.2</td></tr><tr><td>Triglycerides</td><td></td><td>1204 mg/dL</td><td>96.5</td><td>96.9</td></tr><tr><td>Uric Acid</td><td></td><td>30 mg/dL</td><td>98.5</td><td>99.4</td></tr></table>

# Metabolites

N-acetyl zonisamide (NAZ) and the non-glucuronidated 2-sulfamoylacetyl phenol (SMAP) were evaluated. Metabolites NAZ and SMAP-glucuronide are found primarily in urine of patients administered zonisamide therapy. They have not been detected in plasma. Crossreactivity was evaluated in the presence of Low $( 1 5 ~ \mu \varrho / \mathrm { m L } )$ and High $( 4 5 \mu \mathrm { g } / \mathrm { m L }$ zonisamide.

<table><tr><td rowspan=2 colspan=1>Metabolite</td><td rowspan=2 colspan=1>MetaboliteCone(μg/mL)</td><td rowspan=1 colspan=2>PercentageCross-Reactivity</td><td rowspan=1 colspan=2>PercentageInterference</td></tr><tr><td rowspan=1 colspan=1>LowZonisamide</td><td rowspan=1 colspan=1>HighZonisamide</td><td rowspan=1 colspan=1>LowZonisamide</td><td rowspan=1 colspan=1>HighZonisamide</td></tr><tr><td rowspan=2 colspan=1>NAZ</td><td rowspan=1 colspan=1>50.0</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>5.5</td><td rowspan=1 colspan=1>5.4</td><td rowspan=1 colspan=1>6.1</td></tr><tr><td rowspan=1 colspan=1>10.0</td><td rowspan=1 colspan=1>5.3</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>0.7</td></tr><tr><td rowspan=2 colspan=1>SMAP</td><td rowspan=1 colspan=1>50.0</td><td rowspan=1 colspan=1>18.2</td><td rowspan=1 colspan=1>19.5</td><td rowspan=1 colspan=1>57.1</td><td rowspan=1 colspan=1>20.6</td></tr><tr><td rowspan=1 colspan=1>10.0</td><td rowspan=1 colspan=1>14.8</td><td rowspan=1 colspan=1>27.3</td><td rowspan=1 colspan=1>8.8</td><td rowspan=1 colspan=1>5.8</td></tr></table>

Zonisamide-selective antibody did not crossreact with other anti-epileptic or coadministered drugs tested. A high concentration of each compound was spiked into normal human serum with known levels of zonisamide (approximately 15 and $4 5 ~ { \mu \mathrm { g / m L } } )$ and assayed along with a serum control of zonisamide. Measurement of zonisamide resulted in $\leq 1 0 \%$ error in the presence of drug compounds at the levels tested.

<table><tr><td rowspan=2 colspan=1>Compound</td><td rowspan=2 colspan=1>Concentration(μg/mL)</td><td rowspan=1 colspan=2>Percentage Recovery</td></tr><tr><td rowspan=1 colspan=1>15 μg/mLZonisamide</td><td rowspan=1 colspan=1>45 μg/mLZonisamide</td></tr><tr><td rowspan=1 colspan=1>2-Ethyl-2-phenylmalonamide</td><td rowspan=1 colspan=1>1000</td><td rowspan=1 colspan=1>98.4</td><td rowspan=1 colspan=1>100.2</td></tr><tr><td rowspan=1 colspan=1>Acetaminophen</td><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>98.7</td><td rowspan=1 colspan=1>98.7</td></tr><tr><td rowspan=1 colspan=1>Acetyl Salicylic Acid</td><td rowspan=1 colspan=1>1000</td><td rowspan=1 colspan=1>100.3</td><td rowspan=1 colspan=1>102.3</td></tr><tr><td rowspan=1 colspan=1>Caffeine</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>97.0</td><td rowspan=1 colspan=1>97.5</td></tr><tr><td rowspan=1 colspan=1>Carbamazepine-10, 11-epoxide</td><td rowspan=1 colspan=1>120</td><td rowspan=1 colspan=1>99.9</td><td rowspan=1 colspan=1>100.9</td></tr><tr><td rowspan=1 colspan=1>Carbamazepine</td><td rowspan=1 colspan=1>120</td><td rowspan=1 colspan=1>101.7</td><td rowspan=1 colspan=1>100.8</td></tr><tr><td rowspan=1 colspan=1>10-Hydroxy Carbamazepine</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>96.6</td><td rowspan=1 colspan=1>93.5</td></tr><tr><td rowspan=1 colspan=1>Clonazepam</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>99.1</td></tr><tr><td rowspan=1 colspan=1>Cyclosporin A</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>101.2</td><td rowspan=1 colspan=1>104.9</td></tr><tr><td rowspan=1 colspan=1>Diazepam</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>98.0</td><td rowspan=1 colspan=1>100.8</td></tr><tr><td rowspan=1 colspan=1>Erythromycin</td><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>101.4</td><td rowspan=1 colspan=1>103.9</td></tr><tr><td rowspan=1 colspan=1>Ethosuximide</td><td rowspan=1 colspan=1>1000</td><td rowspan=1 colspan=1>99.9</td><td rowspan=1 colspan=1>100.5</td></tr><tr><td rowspan=1 colspan=1>Felbamate</td><td rowspan=1 colspan=1>1000</td><td rowspan=1 colspan=1>94.3</td><td rowspan=1 colspan=1>102.4</td></tr><tr><td rowspan=1 colspan=1>Gabapentin</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>100.9</td><td rowspan=1 colspan=1>105.3</td></tr><tr><td rowspan=1 colspan=1>Heparin</td><td rowspan=1 colspan=1>200 units/mL</td><td rowspan=1 colspan=1>104.1</td><td rowspan=1 colspan=1>102.7</td></tr><tr><td rowspan=1 colspan=1>Ibuprofen</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>101.3</td><td rowspan=1 colspan=1>105.9</td></tr><tr><td rowspan=1 colspan=1>Lamotrigine</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>99.8</td></tr><tr><td rowspan=1 colspan=1>Levetiracetam</td><td rowspan=1 colspan=1>400</td><td rowspan=1 colspan=1>95.6</td><td rowspan=1 colspan=1>97.9</td></tr><tr><td rowspan=1 colspan=1>L-Tryptophan</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>102.9</td><td rowspan=1 colspan=1>104.7</td></tr><tr><td rowspan=1 colspan=1>Oxcarbazepine</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>99.1</td><td rowspan=1 colspan=1>105.2</td></tr><tr><td rowspan=1 colspan=1>Phenobarbital</td><td rowspan=1 colspan=1>400</td><td rowspan=1 colspan=1>98.6</td><td rowspan=1 colspan=1>101.9</td></tr><tr><td rowspan=1 colspan=1>Phenytoin</td><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>105.1</td><td rowspan=1 colspan=1>106.7</td></tr><tr><td rowspan=1 colspan=1>Primidone</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>98.3</td><td rowspan=1 colspan=1>98.8</td></tr><tr><td rowspan=1 colspan=1>Salicylic Acid</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>104.7</td><td rowspan=1 colspan=1>106.6</td></tr><tr><td rowspan=1 colspan=1>Sulfamethoxazole</td><td rowspan=1 colspan=1>400</td><td rowspan=1 colspan=1>102.0</td><td rowspan=1 colspan=1>105.2</td></tr><tr><td rowspan=1 colspan=1>Sulfisoxazole</td><td rowspan=1 colspan=1>1000</td><td rowspan=1 colspan=1>95.8</td><td rowspan=1 colspan=1>98.3</td></tr><tr><td rowspan=1 colspan=1>Theophilline</td><td rowspan=1 colspan=1>250</td><td rowspan=1 colspan=1>101.7</td><td rowspan=1 colspan=1>100.3</td></tr><tr><td rowspan=1 colspan=1>Tiagabine</td><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>102.2</td><td rowspan=1 colspan=1>103.5</td></tr><tr><td rowspan=1 colspan=1>Topiramate</td><td rowspan=1 colspan=1>250</td><td rowspan=1 colspan=1>101.7</td><td rowspan=1 colspan=1>105.0</td></tr><tr><td rowspan=1 colspan=1>Trimethoprim</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>101.1</td><td rowspan=1 colspan=1>96.3</td></tr><tr><td rowspan=1 colspan=1>Valproic Acid</td><td rowspan=1 colspan=1>1000</td><td rowspan=1 colspan=1>99.8</td><td rowspan=1 colspan=1>101.2</td></tr></table>

# Anticoagulants

Studies were conducted to determine the performance characteristics of the assay for both serum and plasma samples containing zonisamide.

The results indicate that there is no significant difference between the recovery of zonisamide in serum or plasma.

# Sample Stability

Serum specimens were shown to be stable for at least twenty-four (24) hours at room temperature $( 2 2 ^ { \circ } \mathrm { C } )$ , twenty-eight (28) days when refrigerated $( 2 { - } 8 ^ { \circ } \mathrm { C } )$ , fifty six (56) days frozen, and after three (3) successive freeze/thaw cycles.

# On-Board Stability

Calibration Curve Stability:A stored calibration was efective up to 46 days based on suppting data.

Reagent on-board stability: Reagents were efective when stored after transfer to analyzer specific reagent containers for up to at least 32 days uncapped and 46 days capped based on supporting data. In-use stability of calibrator and controls was also demonstrated.

# 807.92 (b)(3): Conclusions from Nonclinical Testing

As summarized above, the ARK Zonisamide Assay, the ARK Zonisamide Calibrator and the ARK Zonisamide Control are substantially equivalent to the $\mathrm { Q M S @ }$ Zonisamide assay system. The ARK Zonisamide Assay system was shown to be safe and effective for its intended use based on performance studies.

ARK Diagnostics, Inc. c/o Mr. Johnny Valdez President 1190 Bordeaux Drive Sunnyvale, CA 94089

Re: k091884 Trade name: ARK Zonisamide Assay, Zonisamide Calibrator, ARK Zonisamide Control Regulation Number: 21 CFR 862.3350 Regulation Name: Diphenylhydantoin Test System Regulatory Class: Class II Product Code: NWM, DLJ, LAS Dated: November 11, 2009 Received: November 12, 2009

Dear Mr. Valdez:

We have reviewed your Section $5 1 0 ( \mathbf k )$ premarket notification of intent to market the device referenced above and have determined the device is substantialy equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket. surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (301) 796-5760. For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or ( 301 ) 796-5680 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Cc

Courtny C. Harper, Ph.D.   
Director   
Division of Chemistry and Toxicology   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and Radiological Health

Enclosure

# Indication for Use

# 510(K) Number (if known): K091884

# Device Name:

ARKTM Zonisamide Assay ARKTM Zonisamide Calibrator ARKTM Zonisamide Control

# Indications for Use:

The ARK™ Zonisamide Assay is a homogeneous enzyme immunoassay intended for the quantitative determination of Zonisamide in human serum or plasma on automated clinical chemistry analyzers.

Zonisamide concentrations can be used as an aid in management of patients treated with zonisamide.

The ARK™M Zonisamide Calibrator is intended for use in calibration of the ARK Zonisamide Assay.

The ARK™M Zonisamide Control is intended for use in quality control of the ARK Zonisamide Assay.

Prescription Use X (21 CFR Part 801 Subpart D)

And/Or

Over the Counter Use (21 CFR Part 801 Subpart C)

Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)

![](images/cc3e3146e7913c588fb7dcc2c2bd29bd8e0b0ec735facc8c210ef76e49fe6294.jpg)

DWision Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety